S*BIO becomes Singapore's first biotech company to initiate clinical trial of novel anti-cancer drug
The Phase I trial of SB939 is a dose-escalation study and is currently conducted at the Department of Hematology-Oncology, The Cancer Institute@National University Hospital (TCI@NUH) in Singapore. This study will evaluate the safety and tolerability, as well as determine the pharmacokinetic and pharmacodynamic profile of SB939 in cancer patients. SB939 has been found to be well tolerated in the first cohort of patients and the dosing continues with the next dose-groups. This clinical study involves patients with either solid or hematological tumors.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.